Biogen director granted 2,005 restricted stock units
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
Biogen director Maria C. Freire received an equity award of 2,005 shares of common stock in the form of restricted stock units. The grant carried no purchase price and represents compensation rather than an open-market trade. Following this award, she directly owns 8,820 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 anniversary of the grant date.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 2,005 | $0.00 | $0.00 |
Footnotes (1)
- F1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
Key Figures
Key Terms
restricted stock units financial
Common Stock financial
grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Biogen (BIIB) director Maria C. Freire report?
What is the vesting schedule for Maria C. Freire’s new Biogen (BIIB) restricted stock units?
Was Maria C. Freire’s Biogen (BIIB) transaction an open-market stock purchase?
What type of security did Maria C. Freire receive from Biogen (BIIB)?
AI-generated analysis. How Rhea-AI works. Not financial advice.